FTY-720 Novartis/Yoshitomi

Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 314-331

  Dumont, F J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD; RAPAMYCIN; TACROLIMUS;

AUTOIMMUNE DISEASE; BRADYCARDIA; CLINICAL TRIAL; COUGHING; DRUG METABOLISM; DRUG SYNTHESIS; DYSPNEA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTOPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

EID: 0033846969     PISSN: 14648474     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (133)

1. Design, synthesis, and structure-activity relationships of 2-substiuted-2-amino- 1,3-propanediols: Discovery of a novel immunosuppressant, FTY720
2. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity
3. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immuno-suppressant, FTY720
4. 2-Substituted 2-aminoethanol: Minimum essential structure for immunosuppressive activity of ISP-I (myriocin)
5. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats
6. FTY720, a novel immunosuppressant possing unique mechanisms. II long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A
7. FTY720, a novel immunosuppressant, possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A
8. FTY720, a novel immunosuppressant possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats
9. Yoshitomi to market Zensei's UDCA preparation
10. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols
11. 2-Aminoalcohol immunosuppressants: Structure-activity relationships
12. Long term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720
13. Design, synthesis, and structure activity relationship of 2-substituted 20-amino-1, 3-propanediols/discovery of a novel immunosuppressant, FTY720
14. Fungal metabolites, Part 12: Potent immunosuppressant, 14-deoxymyriocin, and structure-activity relationships of myriocin derivatives
15. FTY720, a novel immunosupressant possessing unique mechanisms, pharmacological activities in several autoimmune and inflammatory models
16. IVAX Announces 1997 First Quarter Results
17. Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720
18. Novartis licenses Yoshitomi's immunosuppressant
19. Yoshitomi expects sales of Y10 billion for Pafnol
20. Yoshitomi licenses out new immunosuppressant to Novartis
21. Novartis to discuss key discoveries of anti-rejection studies at annual transplant meetings
22. Immunology - 10th International Congress (Part II), New Delhi, India
23. 18th Symposium on Medicinal Chemistry by The Pharmaceutical Society of Japan/7th Annual Meeting of the Division of Medicinal Chemistry (Japan) (PART IIC), Kyoto, Japan
24. Ceramide derivatives as therapeutic agents
25. Return on invested capital
26. Novartis: Volume 1 of 2
27. Current pharmaceutical topics and blockbusters from Japan (part I)
28. Current pharmaceutical topic and blockbusters from Japan (part II)
29. Studies of novel anti-rejection therapies gain ground; Novartis to discuss key data at annual transplant meeting
30. Novartis
31. Novartis R and D Investor Seminar, New York
32. Section B: New uses and formulations of known compounds
33. Yoshitomi's immunosuppressant looks promising
34. Yoshitomi's new drugs R and D pipeline
35. Yoshitomi: Profits post large increases due to good performances of mainstays
36. New trends in clinical and experimental immunosuppression - Fourth International Conference (Part II), Geneva, Switzerland
37. Novartis: Getting ready to party
38. Antibody against a novel, myriocin (ISP-I)-based immunosuppressant, FTY720
39. Immunosuppressive agents in organ transplantation: Past, present and future
40. FTY720: A new immunosuppressive agent with novel mechanism(s) of action
41. A novel transplantation drug that modulates lymphocyte traffic rather than activation
42. Human safety and pharmacology of FTY720
43. Safety and pharmacodynamics of multiple doses of FTY720
44. FK506, an immunosuppressant targeting calcineurin function
45. New drugs for the treatment of rheumatoid arthritis
46. Xenotransplantation
47. Preclinical evaluation of a new immunosupressive agent, FTY720
48. The FTY720 story
49. Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: Analogues of FTY720
50. Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro on cardiac allograft survival in rats
51. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. 1. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing
52. Immunosuppressive effects of FTY720 alone or in a combination with cyclosporine and/or sirolimus
53. Mechanism of action of the immunosuppressant, rapmycin
54. Induction on selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720
55. A new immunosuppressant, FTY720, induces bel-2-associated apoptotic cell death in human lymphocytes
56. 2-terminal kinase and p38 pathways durin FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway
57. Cytotoxic actions of FTY720, a novel immunosuppressant, on thymocytes and brain neurons dissociated from the rat
58. An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60
59. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720
60. A novel immunosuppressant, FTY720, increases the efficiency of a superantigen-induced peripheral T-cell deletion whilst inhibiting negative selection in thymus
61. A new immunosuppressant, FTY720, prolongs limb allograft survival in rats
62. Effect of a new immunosuppressant, FTY720, on joint allografts
63. Prevention of graft rejection and graft versus host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation
64. FTY720, a new immunosuppressant, promotes long term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation
65. FTY720, a novel immunosuppressant, inhibits graft arteriosclerosis in a murine heterotopic heart transplant model
66. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces longterm graft acceptance in rat and dog allotransplantation
67. Immunosuppressive action of FTY720 for renal allograft a rat model
68. Dose dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model
69. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: Effect of monotherapy and combined treatment with conventional drugs
70. Effect of pretreatment with FTY720 and cyclosporin on ischemia-reperfusion injury of the liver in rats
71. FTY720: A novel transplantation drug that does not impair immunity to systemic infection, but modulates lymphocytes resposiveness to non-inflammatory chemkines
72. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion and memory
73. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival
74. Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats
75. An immunsuppressive regimen using FTY720 combined with cyclosporin in canaine kidney transplantation
76. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine
77. An effect of FTY720 on acute rejection in canine renal transplantation
78. FTY720, a novel imunosuppressant, shows a synergistic effect in combination with FK506 in rat allograft models
79. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation
80. Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation
81. Effect of FTY720 on immunoregulation in concordant xenotransplantation
82. FTY720 plus CsA inhibits porcine islet xenograft rejection in rats for up to 24 days
83. The peripheral lymphocyte count predicts graft survival in DA to lewis heterotopic heart transplantation treated with FTY720 and RAD
84. Prolonged graft survival induced by CTLA4lg-gene transfection combined with FTY720 administration in rat heart grafting
85. Combination therapy of CTLA4lg-gene transfection combined with FTY720 completely prevent the development of obliterative bronchiolitis and respiratory epithelial cell injury in a murine airway model
86. Induction of tolerance toward rat cardic allografts by treatment with allochimeric class I MHC antigen and FTY720
87. Effect of FTY720, a novel immunosuppressant, on adjuvant - and collagen - induced arthritis in rat
88. Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720
89. Immunosuppressive effect of FTY720 on autoimmune diabetes models
90. Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY 720
91. FTY720 prevents development of experimentental rat autoimmune myocarditis through reduction of circulating lymphocytes
92. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats
93. Role of chemokines in inflammation and immunoregulation
94. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T and B cells and immunosuppression in baboons
95. Time course of leukocyte subsets in rat peripheral blood after single treatment with FTY720
96. Mechanisms of the immunosuppressive and anti-inflammatory effects of glycocorticosteroids
97. Evidence that FTY720 induces T cell apoptosis in vivo
98. FTY720 suppresses immune responses by modulating G-protein coupled receptors resulting in altered lymphocyte homing
99. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing
100. The physiology of lymphocyte migration through the single lymph node in vivo
101. Lymphocyte trafficking and regional immunity
102. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L positive T cells in Peyer's patches by FTY720 induced lymphocyte homing
103. FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecule ICAM-1 in TNF-α treated human umbilical vein endothelial cells
104. Chemokines and cell migration in secondary lymphoid organs
105. Enhanced chemokine-dependent lymphocyte chemotaxis by FTY720 results in immunosuppression
106. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice
107. Immunosuppressant FTY720 inhibits thymocyte emigration
108. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo
109. FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into gafts
110. Role of CYP4F in the metabolic clearance of FTY720 - Prediction of low drug to drug interaction potential
111. Pharmacokinetics / pharmacodynamics (PK/PD) modeling of the trafficking effects of FTY720 on rat immune cells
112. Human pharmacokinetics of FTY720
113. Pharmacokinetic (PK)/ pharmacodynamic (PD) model of FTY720 in humans
114. Absorption and disposition of multiple dose FTY720 in humans
115. Immunosuppressive effect of FTY720 on rat pancreas allograft
116. Beneficial immunosuppressive effect of FTY720 combined with intrathymic injection of splenic cells on rat pancreaticoduodenal allograft
117. Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts
118. Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720
119. Yoshitomi's immunosuppressant looks promising
120. Yoshitomi's new drugs pipeline
121. Yoshitomi: Profits post large increases due to good performance of mainstays
122. Myriocin, a new antifungal antibiotic from Myriococcum albomyces
123. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite
124. Effect of FTY720, a novel immunosuppressant, on adjuvant and collagen induced arthritis in rats
125. FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats
126. FTY720 is efficacious in monkey kidney transplantation
127. FTY720, a novel immunosuppressant possessing unique mechanisms, pharmacological activities in several autoimmune and inflammatory models
128. Therapeutic effect of FTY720 on the clinical course of NZW/W F1 lupus-prone mice
129. The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival
130. A new efficient synthesis of the immunosuppressive agent FTY-720
131. FTY720 blocks allograft rejection by homing of lymphocytes in vivo
132. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation